Intro

This chapter examines the promising clinical trial results of Pfizer's COVID pill, which shows close to a 100% reduction in deaths. It also explores the FDA's delay in reviewing the medication, along with evolving public opinions on crime policies in California and recent developments concerning forced labor imports.